Test Price
2,800 AED✅ Home Collection Available
AICDA Gene (Immunodeficiency with Hyper-IgM Type 2) Genetic Test in UAE | 2800 AED | DHA Guidelines
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- ✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by a board-certified medical geneticist.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
The AICDA gene NGS test detects pathogenic variants responsible for Hyper‑IgM syndrome type 2, a severe primary immunodeficiency. Using Next Generation Sequencing, it provides definitive molecular diagnosis, enabling early intervention and personalized management under DHA‑approved protocols.
| Feature | Our Test (NGS) | Closest Alternative (Sanger) |
|---|---|---|
| Precision | 99.9% Sensitivity & Specificity | ~95% Sensitivity, limited to single exon mutations |
| Methodology | NGS – full gene coverage, copy‑number variant detection | Capillary sequencing, no copy‑number assessment |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Clinical Interpretability | Includes pathogenicity classification (ClinGen/ACMG) | Variant calls only, no clinical annotation |
Physician Insight & Safety Protocols
“As your consultant medical geneticist (DHA: 9294403), I understand the emotional weight of a possible immunodeficiency diagnosis. This test provides critical genetic evidence, but it must be correlated with your immunological work‑up and clinical history. Always review the results with your treating specialist before altering any therapy.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics
Advisory Notice
Do not discontinue prescribed medication or immunoglobulin therapy without consulting your doctor.
Exclusion Criteria & Emergency Red Flags
- Active severe infection requiring hospitalization.
- Inability to provide informed consent (for minors, legal guardian consent is mandatory per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability).
- If any of the following occur after sample collection, seek immediate medical attention: fever >38.5 °C, severe respiratory distress, or signs of sepsis.
Patient FAQ & Clinical Guidance
1. What is the purpose of the AICDA gene test?
This genetic test detects AICDA mutations for Hyper‑IgM syndrome type 2, guiding early treatment decisions and enabling precise genetic counseling.
2. How is the test performed and what does it entail?
At‑home blood sampling and NGS analysis detects AICDA mutations with 99.9% accuracy for reliable diagnosis. The sample is collected via VIP Mobile Phlebotomy and processed in our ISO‑accredited laboratory.
3. What happens if the result is positive?
A positive result confirms Hyper‑IgM type 2, necessitating immunoglobulin replacement therapy and lifelong infection prophylaxis under specialist supervision.
Pre‑requirement: A genetic counselling session to draw a pedigree chart of affected family members is mandatory. Provide complete clinical history and report any bleeding disorders or anticoagulant use.
UAE Regulatory & Data Privacy Adherence
Data Protection: Your genetic information is processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical data is encrypted and accessed only by authorized personnel. DHA Facility License No. 1143 ensures regulatory oversight.
Clinical & Logistical Metadata
| Test Name | AICDA Gene (Immunodeficiency with Hyper-IgM Type 2) Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) – Home collection available via VIP Mobile Phlebotomy |
| Methodology Used | Next Generation Sequencing (NGS) – Full gene coverage including copy-number variant detection |
| ICD-10-CM Code | D80.5 |
| LOINC Code | 55176-5 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE) |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians